Do preeclampsia prediction biomarkers vary in patients of different BMIs?
First Trimester Preterm Preeclampsia Prediction with Metabolite Biomarkers: Differential Prediction According to Maternal Body Mass Index
Recent research suggests that there may be different types of preeclampsia (such as early- versus late-onset, with or without severe features, HELLP syndrome, and postpartum-onset). These type of preeclampsia may also vary based on specific individual risk factors. One risk factor that researchers have identified is a woman's body mass index (aka BMI), a number calculated from a patient's height and weight.
In this study, researchers asked: are there biomarkers (molecules measured in the blood) in early pregnancy that can predict preterm preeclampsia later in pregnancy? And if so, are those biomarkers different in women in different BMI groups (healthy, overweight, obese)? Researchers found distinct levels of certain metabolites (small products of metabolism) in blood drawn in early pregnancy that were linked to developing preterm preeclampsia later in that pregnancy. Interestingly, one metabolite was a form of vitamin D (25-hydroxyvitamin D3). Others were small fatty acids and individual amino acids (the building blocks of protein). When comparing metabolites and their ratios to one another among women in different BMI groups, researchers also found among women who went on to develop preterm preeclampsia, that metabolites in early pregnancy were different depending on BMI groups, particularly for women with overweight and obesity.
Take home message: As preeclampsia research continues to move forward at an accelerated pace, research is revealing possible differences not only in “types” of preeclampsia, but also differences in maternal risk profiles. This study suggests that women of different BMI classes might have distinct risk profiles for preeclampsia. More work is needed to refine risk factors for individuals, with the ultimate goal of having an early-pregnancy screening test to predict preeclampsia.
Link: https://www.ajog.org/article/S0002-9378(22)02290-6/pdf
Citation: Tuytten R, Syngelaki A, Thomas G, Panigassi A, Brown LW, Ortea P, Nicolaides KH. First Trimester Preterm Preeclampsia Prediction with Metabolite Biomarkers: Differential Prediction According to Maternal Body Mass Index. Am J Obstet Gynecol. 2022 Dec 17:S0002-9378(22)02290-6. doi: 10.1016/j.ajog.2022.12.012. Epub ahead of print. PMID: 36539025.
About Research Roundup
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Related Articles
Hypertensive disorders of pregnancy significantly increase your risk of developing long-term heart problems. A careful review of blood pressure elevations during and after pregnancy may assist in iden...
Hypertensive disorders of pregnancy (HDP) can affect different groups of women in different ways, and even though we know this happening, we don't fully understand why. There are many factors, like bi...
There is growing evidence that studies examining pregnancy and its complications need to start early within the pregnancy to fully understand the nature of preeclampsia. Key gestational milestones, wh...
It is known that chronic hypertension and high BMI (body mass index) are risk factors for hypertensive disorders of pregnancy (HDP). Studies documenting this risk have usually assessed blood pre...
Several biomarker tests are under development to predict or diagnose preeclampsia. While none of these tests are yet widely accepted in U.S. clinical practice, two FDA-approved tests are available in...